In this study, rat models of wound closure by first and second intention were developed to evaluate the influence that two immunosuppressants for treating multiple sclerosis (fingolimod, azathioprine) have on wound healing. Sixty-three SpragueDawley rats were daily treated with fingolimod (0.6 mg/kg), azathioprine (2.5 mg/kg), or placebo (saline). Following 6 weeks of treatment, a linear incision (1.5 cm) or a circular excisional defect (diameter 1.5 cm) was made on the dorsal skin. The treatments were uninterrupted and after 7 days (incisional) or 21 days (incisional, excisional), animals were euthanized (n = 7 per group and time-point). Morphometric (wound closure), histological (stainings), and immunofluorescent studies (macrophages) were performed to evaluate the healing process. For both the incisional and excisional defects, animals treated with fingolimod exhibited a healing process equivalent to that of placebo in terms of collagenization, wound closure, and macrophage response. By comparison, groups treated with azathioprine displayed a delay in healing times which was especially evident in the excisional defect, where inflammatory reaction and collagen deposition in the repair tissue remained active by day 21. These results show that immunosuppressants with a selective mechanism of action (fingolimod) can have less impact on wound healing than their classical nonselective counterparts (azathioprine).
INTRODUCTION
Wound repair, also known as wound healing, is a reparative process that is triggered in virtually all tissues following an injury. 1 This complex and dynamic event has been characterized as having four overlapping phases: (1) hemostasis, (2) inflammation, (3) proliferation, and (4) maturation and tissue remodeling. 2 Throughout the processes, coordinated interactions occur among several biochemical and biological elements, including soluble mediators, blood coagulation factors, immune cells, connective tissue cells, and extracellular matrix (ECM) components. 1, 3 In the case of cutaneous healing, especially when the lesions involve the entire tegument thickness, the healing process is highly important to ensure tissue homeostasis. [4] [5] [6] Following skin injury, damaged vessels constrict, and vascular cells activate a coagulation cascade, resulting in the formation of a clot that contains platelets, collagen, and various proteins, such as fibrin, thrombin, and fibronectin. 3 Once the vessels are clotted, the vascular permeability increases, and several cytokines and growth factors are released, thus triggering the inflammatory phase. 6 Cell signaling, which is mediated by cytokines such as interleukins, tumor necrosis factor-α, and transforming growth factor-β, promotes leukocyte migration into the damaged area, 3 where monocytes gradually differentiate into macrophages. These phagocytic cells play critical roles in the initiation, maintenance, and resolution of tissue repair. 7 The interaction between injured ECM and activated macrophages provides biochemical support for the subsequent processes of cell proliferation, mainly keratinocytes, fibroblasts, and endothelial cells; angiogenesis, which is mediated by vascular endothelial growth factor; and synthesis of new ECM during tissue remodeling. 3, 6 The phenomenon of normal healing is directly related to the presence of inflammatory cells, mainly neutrophils, macrophages, and mast cells. [8] [9] [10] Analyzing the evolution of these populations helps in determining the state of repair. Macrophages adopt different phenotypes in response to different factors being present during the tissue repair process. 11 The differentiation of macrophages is directed toward the M1 and Wound Rep Reg (2019) 27 59-68 © 2018 by the Wound Healing Society M2 phenotypes. M1 has an inflammatory character and predominates in the initial proinflammatory phase of healing because this phenotype is the predominant phenotype at the beginning of the inflammatory response. M2 is involved in the late phenomena of inflammation and promotes granulation. M2 macrophages also promote angiogenesis and ECM synthesis and scar formation. 10, 12 Together with the activation of macrophages and the release of key cytokines and growth factors, the inflammatory phase is responsible for protecting the wound against infection or debridement, 13, 14 so this phase is a crucial stage for the correct development of wound healing. There are, however, both intrinsic and environmental factors that might interfere with the inflammatory phase, thereby affecting or even impairing the healing process. In this regard, it is well documented that drugs such as immunosuppressants do modulate or inhibit different biological processes during tissue healing. 15, 16 Immunosuppressive therapy is increasingly being used in clinical practice and has been shown to affect wound healing to varying degrees. 16 Multiple sclerosis is a demyelinating, inflammatory, chronic, and degenerative central nervous system disease. 17 All patients with multiple sclerosis-as well as other autoimmune diseases requiring immunosuppressantswho are undergoing surgery should be monitored carefully for the development of infection, wound dehiscence and other healing complications. Data are limited, particularly with the newer drugs, regarding the use of immunomodulating therapy in the perioperative period. In some cases, the decisionmaking process relies on the extrapolation of results from animal studies to clinical practice. 15 Moreover, frequently, information on the effects of newer immunosuppressants on wound healing is absent. Currently in Europe, there is a wide variety of approved immunosuppressant drugs for the treatment of multiple sclerosis 18 but no studies have been published on their effect on wound healing. Considering that multiple sclerosis is a chronic disease mostly diagnosed in the third decade of life, there is a high probability for patients suffering from multiple sclerosis of needing an elective or emergency surgery during their lifetime while under immunosuppressive treatment.
Azathioprine and fingolimod are two therapeutic agents used to treat multiple sclerosis. The former, a classical immunosuppressant, is a purine analogue that interferes with DNA synthesis and inhibits the proliferation of various types of immune cells. 19 The latter is a structural analogue of sphingosine that prevents lymphocyte egress from lymphoid tissues in a selective fashion, thereby reducing their infiltration into the central nervous system. 20 Given their immunomodulatory activity, these two drugs may have an impact on the normal evolution of cutaneous healing and thus their interaction with wound healing should be determined. For this reason, we conducted a morphological evaluation of the effects that both azathioprine and fingolimod have on wound repair in a murine model of cutaneous healing by primary and secondary intention.
MATERIAL AND METHODS

Experimental animal
Female Sprague-Dawley rats (n = 63) were used as the experimental animal, and they weighed approximately 250 g at the beginning of the study. The animals were managed according to the current national and international regulations on 
Administered drugs
The following drugs were used, the doses of which were adjusted to approximate their equivalent use in humans:
• Fingolimod (Gilenya ® ; Novartis Pharmaceuticals S.A., Basel, Switzerland): Dose 0.6 mg/kg.
• Azathioprine (Imurel ® ; UCB Pharma S.A., Brussels, Belgium): Dose 2.5 mg/kg.
• Placebo: Saline solution (sodium chloride 0.9%).
Study and treatment groups
The animals were randomly distributed into three study groups (n = 21), depending on the pharmacological treatment administered. All animals received a daily dose of placebo or the corresponding drug, diluted in saline solution to a volume of 0.5 mL, administered orally by cannulation. This administration was maintained uninterrupted for 6 weeks prior to the development of an incisional or excisional cutaneous defect, which was applied to the dorsal area. In each treatment group, the animals were again divided according to two surgical models ( Figure 1A ).
Anesthetic technique
The anesthetic procedure was the same for the two surgical models employed. The animals were anesthetized in an inhalation chamber by a mixture of isoflurane (Forane ® ; AbbVie S.L.U., Madrid, Spain) at 4-5% and oxygen at a flow rate of 1 L/minute. During the surgery, anesthesia was maintained by a face mask connected to a calibrated vaporizer, providing an inhalation dose of isoflurane of 1-2%.
Surgical models and experimental design
Two surgical models were employed to independently evaluate the tissue healing process by first and second intention.
Incisional defect model
Fourteen animals were randomly selected from each treatment group. Prior to anesthesia and after shaving the animal, a linear incision of 1.5 cm in length, centered and approximately 0.5 cm caudal to the scapulae was made. The incision was then sutured using sterile Manipler S-2 stainless steel staples (Mani ® Inc., Tochigi, Japan) ( Figure 1B ). The animals did not require postoperative analgesia.
Excisional defect model
The remaining seven animals from each treatment group were used in the development of this model. Prior to anesthesia and after shaving the animal, in the same anatomical location described previously, a circular defect of 1.5 cm in diameter was made that covered the entire thickness of the skin, which had been previously marked by a calibrated metallic punch ( Figure 1C ). The animals did not require postoperative analgesia.
The selected study times varied according to the surgical model used. In the incisional defect group, the study times evaluated were 7 and 21 days, and in the excisional defect group, the study time was only 21 days. The final size of each experimental group was seven animals per treatment, defect, and study time.
Throughout the study period, the animals continued to receive daily doses of the drug as previously described. After reaching the corresponding study time, the animals were euthanized in a CO 2 inhalation chamber. At the time of euthanasia, the scar tissue was photographed for morphometric evaluation and was subsequently excised. The tissue samples were sectioned into two halves transverse to the body axis for histological processing.
Morphometric studies
At the time of euthanasia, a macroscopic assessment of scar tissue was performed. For each treatment group, the evolution of healing between 7 and 21 days in the animals in the incisional defect model group was qualitatively compared. In the case of the excisional defect, a morphometric study was carried out to assess the wound closure after 21 days of the intervention. For this assessment, the initial area of the defect caused at the time of surgery (diameter 1.5 cm) and the area of the defect that remained unclosed after 21 days were measured using the image analysis program ImageJ (National Institute of Health; http://imagej.nih.gov/ij/). With the values obtained from both measurements, the percentage of total wound healing was determined for each animal, according to the following calculation: % healing = 100 − [open area at 21 days × 100/initial area].
Morphological studies
The tissue samples obtained were fixed with solution F13 (60% ethanol, 20% methanol, 7% polyethylene glycol, 13% distilled water). After fixation, the samples were dehydrated with alcohol of increasing concentration and embedded in paraffin. The paraffin blocks were cut with a Microm HM-325 microtome (Microm International GmbH, Walldorf, Germany) into 6-μm-thick sections. Finally, the sections were dewaxed, rehydrated, and stained with hematoxylin-eosin (HE), Masson's trichrome-Goldner-Gabe variant-(MT), and Sirius Red (SR) for examination under a Zeiss Axiophot light microscope (Carl Zeiss, Oberkochen, Germany). Both HE and MT allowed for the general observation of the repairing tissuedistribution of collagen, granulation tissue, inflammatory cells, skin appendages, and neoformed vessels. The SR staining was utilized to evaluate the organization and maturation of collagen fibers in the repairing tissue. With SR, immature collagen (type III collagen) exhibits a green-yellowish tone, while the mature collagen (type I collagen) acquires a reddish tone.
Epithelial thickness
The HE and MT stained tissue slides were utilized to measure the thickness of the epithelial layer in the different study groups. Using the microscope's Axiovision LE Digital Image Processing Software (Carl Zeiss), several measurements of the epithelium (200× magnification) were done in between both defect margins. A total of 10 and 30 measurements were collected for each of the incisional-model and excisional-model specimens, respectively. These measurements were carried out perpendicular to the epithelium, starting at the basal layer and projecting toward the skin surface. Those areas of the epidermis disrupted by appendages, containing exfoliated cell layers, or covered by fibrin clots were not recorded. Additional measurements of the epithelium belonging to the edges of the tissue sections were measured to determine the thickness of the nondamaged epidermis.
Immunodetection of macrophages
The presence of macrophages in the scar tissue was evaluated by double immunofluorescence techniques. Monoclonal antibodies against CD68 (clone ED1, AbD Serotec, Bio-Rad Laboratories Inc., Hercules, CA) and CD206 (Abcam, Cambridge, UK) were used. The former is a global marker of macrophages and the latter is a marker associated with macrophages that present a M2 repair phenotype. After blocking nonspecific binding sites with 3% bovine serum albumin, the tissue sections were incubated for 2 hours at 37 C with a reaction mixture containing the anti-CD68 (1/200) and anti-CD206 (1/200) antibodies. After washing, the tissues were incubated again with a mixture of secondary antibodies conjugated to fluorochromes, rhodamine (red marker) for CD68 and fluorescein-5-isothiocyanate (FITC) (green marker) for CD206. Cell nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole. Samples were examined under a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) to detect fluorescence. This work was performed by the Confocal Microscopy Service (ICTS 'NANBIOSIS' U17) of the Biomedical Research Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN at the University of Alcalá, Madrid, Spain) (www.uah.es/enlaces/ investigacion.shtm).
A combination of these markers was utilized to determine the number of macrophages present in the tissue (CD68 + / CD206 − ) and the fraction of these macrophages exhibiting the M2 phenotype (CD68 + /CD206 + ). In each sample analyzed, 20 randomly chosen fields (200× magnification) were quantified, and the result was expressed as the number of M2 phenotype macrophages vs. the total number of quantified non-M2 macrophages.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5 software for Windows (GraphPad Software, Inc., La Jolla, CA). The data were expressed as the mean AE SEM. To compare the respective treatments with one another, the analysis of variance (ANOVA) was used, with the Bonferroni correction as the post hoc test. To compare the effect of a given treatment over time, the Mann-Whitney U test was used. In all cases, a significance level of p < 0.05 was used.
RESULTS
Macroscopic evaluation
None of the animals included in this study showed local or systemic symptoms of surgical site infection, regardless of the surgical model developed or the pharmacological treatment received. All animals completed the assigned study time, with the sole exception of one individual belonging to the azathioprine 21-day study group in the incisional defect model. Therefore, this animal was excluded from the subsequent macro-and microscopic assessments.
Incisional defect
After 7 days of the intervention, the animals in the placebo group showed a normal-looking wound closure, with no apparent disruption of the scar. In contrast, macroscopic observations showed a slight separation between the wound edges in two animals treated with fingolimod (2/7, disruption 28.57%) and in five treated with azathioprine (5/7, disruption 71.43%). After 21 days, the wound was completely closed in all animals ( Figure 2A ).
Excisional defect
After 21 days of surgery, all animals treated with placebo, fingolimod, or azathioprine had very similar scar tissue. The edges of the defect were contracted, and the wound was mostly closed, with a small open surface remaining in the central region of the defect ( Figure 2B ). Morphometric analyses revealed a larger wound closure area in the placebo group (94.98 AE 0.71%), followed by fingolimod (92.97 AE 0.68%) and azathioprine (91.96 AE 1.14%). No significant differences were observed between any of these treatments.
Morphological results
The histological studies allowed the process of tissue healing to be evaluated in the different study groups. Some differences were observed in the distribution and composition of the scar tissue, depending on the treatment received and the surgical model used.
Incisional defect
At 7 days, the behavior of the groups treated with placebo, fingolimod, and azathioprine was similar. The presence of granulation tissue around the wound was observed, as was the inflammatory exudate at the upper edge of the incision. In the tissue borders adjacent to the injured area, a lower presence of cutaneous appendages and a thickening of the epidermis were observed. The scar tissue presented accumulations of inflammatory cells distributed along the axis of the incision, small neoformed vessels and a deposit of immature collagen that was organized in a heterogeneous manner ( Figure 3A) . After 21 days, the groups treated with placebo and fingolimod presented scar tissue that looked similar to healthy tissue and was occasionally only distinguishable by the decreased presence of cutaneous appendages in the repaired area. By contrast, the group treated with azathioprine showed evidence of a healing process that was still in development, including the presence of inflammatory cells, epithelial thickening, and a greater presence of immature collagen deposit than was observed with the other treatments ( Figure 3B ).
Excisional defect
This model was more aggressive than the incisional one, therefore, the reparative process was not complete at 21 days in any of the study groups analyzed. The presence of fibrin clot remained, and inflammatory exudate could be observed in the upper margin of the wound and was located in the central portion that had not yet healed. Under the epidermis, the newly formed tissue contained very few skin appendages and had various accumulations of inflammatory cells that were more evident in the group treated with azathioprine. In this study group, there was a prevalence of immature collagen along the repairing tissue, while both placebo and fingolimod groups mainly exhibited mature collagen (Figure 4 ).
Epithelial thickness
All the specimens belonging to the different study groups displayed a quantifiable epithelial thickening along the defect area.
Incisional defect
Results observed at day 7 revealed a thicker epithelial layer in the groups treated with azathioprine (108.30 AE 24.85 μm) and fingolimod (100.60 AE 9.67 μm) compared to placebo (74.56 AE 14.23 μm), although these differences were not statistically significant among any of the study groups. By day 21, there was a similar thickness in the placebo group (79.82 AE 5.30 μm) than the recorded at the previous timepoint, while both azathioprine (64.24 AE 10.56 μm) and fingolimod (55.05 AE 11.69 μm) exhibited epithelial thinning, which was especially relevant for fingolimod (p < 0.05). Measurements of the nondamaged tissue (40.28 AE 2.90 μm and 33.59 AE 2.06 μm for days 7 and 21, respectively) revealed a significantly lower thickness of this cell layer compared to both azathioprine plus fingolimod groups at day 7 (p < 0.001), as well as to placebo at day 21 (p < 0.01) ( Figure 5A ).
Excisional defect
In this model, the thickest epithelium was recorded for azathioprine (65.93 AE 8.29 μm), followed by placebo (61.35 AE 3.15 μm) and fingolimod (55.41 AE 8.35 μm) groups. As observed previously, there were no statistical differences among the three study groups, although all of them were significantly thicker (p < 0.001) than the nondamaged epidermis (22.21 AE 1.13 μm) ( Figure 5B ).
Macrophagic response
Double immunofluorescence was performed to quantify the global macrophage response, distinguishing between subpopulations of macrophages with the non-M2 phenotype (CD68 + /CD206 − ) and the M2 (CD68 + /CD206 + ) phenotype ( Figure 6 ). Representative pictures of all the study groups can be observed as a Supporting Information Figure S1 .
Regardless of the experimental model (incisional and excisional), treatment (placebo, fingolimod, and azathioprine), and study time (7 and 21 days), the proportion of M2 macrophages was significantly lower than that of non-M2 in all groups (p < 0.001). Analysis of each of these subpopulations independently revealed some differences, which are described below.
Incisional defect
At 7 days, the placebo group presented a large amount of macrophagic cells in the granulation tissue, with cluster formation observed in the most superficial areas and near the edge of the incision. This distribution was similar in the fingolimod group, although the latter had fewer macrophages. For azathioprine, the presence of macrophages was reduced, more isolated and dispersed by the connective tissue. After 21 days, a general decrease in the global macrophage population was observed in the three study groups. Analysis of the macrophagic subpopulations according to their phenotype showed that the non-M2 macrophages decreased sharply in the placebo (p < 0.01) and fingolimod (p < 0.001) groups but that the decrease was more gradual in the group treated with azathioprine (p < 0.05) ( Figure 6A ). The behavior was different in the M2 subpopulation: whereas these macrophages decreased in the placebo (p < 0.01) and fingolimod (p < 0.01) groups, they increased significantly at 21 days in the group treated with azathioprine (p < 0.05) ( Figure 6B ).
Excisional defect
Macrophagic cells formed clusters throughout the scar tissue, both in the more superficial regions close to the 
DISCUSSION
For decades, the development of animal models has been essential for elucidating the complex process of wound healing under both normal and impaired conditions. Based on previous experience from our group, [21] [22] [23] [24] we developed a murine model to evaluate both the initial phases of healing (7 days) and tissue remodeling (21 days) by using one incisional and one excisional model (healing by first intention and by second intention, respectively).
According to Miao et al., incisional defects can be considered as the simplest wounds to be repaired 25 given the shorter healing time involved and the lower inflammatory response compared to other more severe models. Such is the case of the excisional model (involving the entire thickness of the skin), that requires all repair phases to heal, thus allowing the repair mechanisms to be studied in their entirety and indicating problems or even delays in the process.
In both models, animals were treated daily with a placebo solution or immunosuppressants (azathioprine, fingolimod) using doses equivalent to those administered in humans. The dose of azathioprine (2.5 mg/[kg day]) was the same as that used by Chiquetti et al. in their evaluation of the effect of immunosuppressants on cutaneous healing in rats. 26 They observed that a 3-week azathioprine treatment prior to surgery was sufficient to achieve biological activity in medicated animals. In our study, to ensure that any biological effect observed would be from azathioprine, we doubled the number of weeks of pretreatment to 6 weeks. For fingolimod, its effect in rats was dose-dependent and was obtained at both the vascular 27 and the immune system levels 28 at a dose of 0.3 mg/(kg day). To determine whether fingolimod had harmful effects on healing, we doubled the dose, administering 0.15 mg/day to rats weighing 250 g (which is equivalent to one dose of 0.6 mg/[kg day]). In a normal wound healing process, during the first days after the debridement of the wound by inflammatory cells, the injured dermis increases in volume to form granulation tissue over the damaged area. 3, 29 The results of our study revealed some morphological differences between the groups treated with the two immunosuppressants. In both models, animals treated with fingolimod behaved in a similar manner as did from the placebo groups, whereas the animals treated with azathioprine exhibited less collagenization and reduced granulation tissue formation, as well as less organized angiogenesis and fewer skin appendages in the wound area. These differences may have occurred because the fingolimod-associated decrease on lymphocytes 30 was insufficiently strong to impair the granulation tissue formation, thus allowing the activation of macrophages and the progression of healing. Despite these differences, the morphometric evaluation of the wound contraction revealed similar behavior, regardless of the drug administered. Taken together, these data suggest that there was no histological interference of fingolimod in the formation of the scar, thus supporting the notion that healing in azathioprine groups was delayed compared to those of the other two groups, which agrees with previous findings from other experimental studies using this immunosuppressant. 26, 31 Of the two predominant cell lines in the inflammatory phase of healing, neutrophils, and macrophages, we focused our study on the analysis of macrophages. The reason was twofold: first, the early proinflammatory but proregenerative delay allowed us to assess the speed of the healing process. Second, fingolimod is a selective immunosuppressive drug that does not act on neutrophils because its mechanism of action is specific to sphingosine-1-phosphate (S1P) receptors; thus, it mainly affects T, B and natural killer lymphocytes 30 as well as macrophages. In all groups studied, non-M2 (proinflammatory) macrophages were significantly more numerous than were M2 macrophages (repairers), demonstrating their normal distribution pattern during healing. 32 The results from the incisional model revealed a significant decrease in all non-M2 and M2 macrophages over time, with the exception of only the M2 cells in the azathioprine-treated group, where they increased significantly. The decrease in M2 at 21 days indicates that the proliferation phase had already been completed and, therefore, that the number of these cells had decreased. Their increase in the azathioprine group indicates that the healing tissue of these animals was still in the stage of proliferation and not in the tissue remodeling stage, again suggesting that healing would be delayed in the azathioprine group. It has been described that macrophage-deficient wounds show reduced angiogenesis, altered epithelization and failure in repair 33, 34 which corresponds to our findings in the azathioprine group. In the excisional model, there were no differences in the M2 macrophage count among the three groups because the healing process was more complex and reepithelialization had not yet been completed in any of the three groups, with the proliferation phase still being maintained. A longer study time in this model would be necessary to assess whether the differences in the macrophage counts between groups were maintained and if they correlated to a delay in the animals treated with azathioprine.
In conclusion, a previously described animal experimental model, fingolimod, a selective immunosuppressant with indication for treating relapsing-remitting multiple sclerosis, did not interfere in the healing process of a cutaneous surgical wound, unlike azathioprine, a "classical" immunosuppressant, which produced a delay in healing that was incomplete at the end of the study period.
Similar studies will probably be needed to evaluate the effect on wound healing of all immunosuppressive profile drugs currently utilized for treating the several forms of multiple sclerosis and to understand their safety profiles in both scheduled and emergency surgeries, as well as in traumatic pathologies.
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